Price sustaining above 13 day EMA and close above previous intermediatehighs signaling further upward momentum in coming sessions.

Bullish momentum has resumed which suggestsbullish continuation to persist in the near term.

Sharing information with company's shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company's US business stabilised last ...

The brokerage has cut earnings estimate on Lupin by 2-4%, factoring in lower US revenues due to slow ramp-up of Solosec and weak launch pip...

The analyst suggested a stoploss at Rs 750.

The USFDA said it had inspected the Unit 1 at the Mandideep facility of the company from November 26 to December 4, 2018.

Sell Lupin Ltd. at a price target of Rs 783 and a stoploss at Rs 863 from entry point.

Buy Lupin Ltd. at a price target of Rs 990.0 and a stoploss at Rs 949 from entry point.

Sell Lupin Ltd. at a price target of Rs 875.0 and a stoploss at Rs 895 from entry point.

Buy Lupin Ltd. at a price target of Rs 905.0 and a stoploss at Rs 880 from entry point.

Buy Lupin Ltd. at a price target of Rs 834 and a stop loss at Rs 795 from entry point.

Buy Lupin Ltd. at a price target of Rs 815.0 and a stop loss at Rs 775 from entry point.

Buy Lupin Ltd. at a price target of Rs 960.0 and a stop loss at Rs 812 from entry point.

Buy Lupin at a price target of Rs 880 and a stop loss at Rs 820 from entry point.

Gupta is survived by wife and five children (four daughters and a son) Vinita Gupta, the eldest daughter and Nilesh Gupta were handed over ...

Drug major Lupin expects to strengthen its US pipeline by launching around 20 products in the next fiscal (2014-15).

Lupin Ltd posted nearly three-fold increase in its consolidated net profit at Rs 408.1 crore for the fourth quarter ended March 31, 2013.